Truist Financial Corp Sells 16,398 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Truist Financial Corp decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 1.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,372,424 shares of the company's stock after selling 16,398 shares during the period. Truist Financial Corp owned approximately 0.12% of Teva Pharmaceutical Industries worth $30,248,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. CIBC Asset Management Inc lifted its position in Teva Pharmaceutical Industries by 14.1% during the 4th quarter. CIBC Asset Management Inc now owns 120,328 shares of the company's stock worth $2,652,000 after buying an additional 14,865 shares in the last quarter. Sanctuary Advisors LLC lifted its position in Teva Pharmaceutical Industries by 132.4% during the 4th quarter. Sanctuary Advisors LLC now owns 81,643 shares of the company's stock worth $1,799,000 after buying an additional 46,514 shares in the last quarter. Principal Financial Group Inc. lifted its position in Teva Pharmaceutical Industries by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 92,471 shares of the company's stock worth $2,038,000 after buying an additional 2,752 shares in the last quarter. AustralianSuper Pty Ltd lifted its position in Teva Pharmaceutical Industries by 16.8% during the 4th quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company's stock worth $203,268,000 after buying an additional 1,329,319 shares in the last quarter. Finally, V Square Quantitative Management LLC lifted its position in Teva Pharmaceutical Industries by 21.8% during the 4th quarter. V Square Quantitative Management LLC now owns 19,802 shares of the company's stock worth $439,000 after buying an additional 3,549 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares of the company's stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.55% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Finally, Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $23.57.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded down $0.26 during mid-day trading on Friday, reaching $16.75. The company had a trading volume of 9,628,751 shares, compared to its average volume of 13,052,823. The company has a market cap of $18.97 billion, a P/E ratio of -11.55, a P/E/G ratio of 1.39 and a beta of 0.71. The business has a fifty day simple moving average of $19.92 and a 200 day simple moving average of $18.48. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.61 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.